Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for the Treatment of Active Rheumatoid Arthritis
2021-003958-23Phase 3Active
- Sponsor
- Strasbourg University Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Spironolactone arm with Placebo arm (2 arms). Primary endpoint: Proportion of patients achieving DAS28-CRP < 3.2 at 3 months. Started Aug 2021; status: active.
02
Drugs
spironolactone
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-003958-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003958-23.